A citation-based method for searching scientific literature

Gary Kohanbash, Diego A Carrera, Shruti Shrivastav, Brian J Ahn, Naznin Jahan, Tali Mazor, Zinal S Chheda, Kira M Downey, Payal B Watchmaker, Casey Beppler, Rolf Warta, Nduka A Amankulor, Christel Herold-Mende, Joseph F Costello, Hideho Okada. J Clin Invest 2017
Times Cited: 158



Lenny Dang, David W White, Stefan Gross, Bryson D Bennett, Mark A Bittinger, Edward M Driggers, Valeria R Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C Keenan, Kevin M Marks, Robert M Prins, Patrick S Ward, Katharine E Yen, Linda M Liau, Joshua D Rabinowitz, Lewis C Cantley, Craig B Thompson, Matthew G Vander Heiden, Shinsan M Su. Nature 2009
Times Cited: 2186




List of shared articles



Times cited



Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Padma Kadiyala, Stephen V Carney, Jessica C Gauss, Maria B Garcia-Fabiani, Santiago Haase, Mahmoud S Alghamri, Felipe J Núñez, Yayuan Liu, Minzhi Yu, Ayman Taher,[...]. J Clin Invest 2021
9

Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.
Julie Leca, Jerome Fortin, Tak W Mak. Curr Opin Biotechnol 2021
3

Systemic Immune Bias Delineates Malignant Astrocytoma Survival Cohorts.
Michael Prosniak, Larry A Harshyne, Jonathan Gorky, Mark T Curtis, Lawrence C Kenyon, James S Schwaber, Aurore Lebrun, Rhonda B Kean, David W Andrews, D Craig Hooper. J Immunol 2021
0

Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite.
Raffaela S Berger, Christian J Wachsmuth, Magdalena C Waldhier, Kathrin Renner-Sattler, Simone Thomas, Anuhar Chaturvedi, Hans-Helmut Niller, Elisabeth Bumes, Peter Hau, Martin Proescholdt,[...]. Cancers (Basel) 2021
0

From Metabolism to Genetics and Vice Versa: The Rising Role of Oncometabolites in Cancer Development and Therapy.
Emanuela Di Gregorio, Gianmaria Miolo, Asia Saorin, Agostino Steffan, Giuseppe Corona. Int J Mol Sci 2021
0

The implications of IDH mutations for cancer development and therapy.
Christopher J Pirozzi, Hai Yan. Nat Rev Clin Oncol 2021
1

Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.
Maria B Garcia-Fabiani, Santiago Haase, Andrea Comba, Stephen Carney, Brandon McClellan, Kaushik Banerjee, Mahmoud S Alghamri, Faisal Syed, Padma Kadiyala, Felipe J Nunez,[...]. Front Oncol 2021
0

Immunometabolism: A 'Hot' Switch for 'Cold' Pediatric Solid Tumors.
Lin Xiao, Harrison Yeung, Michelle Haber, Murray D Norris, Klaartje Somers. Trends Cancer 2021
0


IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
Xiao Xiang, Ziyang Liu, Chong Zhang, Zhao Li, Jie Gao, Changkun Zhang, Qi Cao, Jinghui Cheng, Hengkang Liu, Dingbao Chen,[...]. Adv Sci (Weinh) 2021
1

Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma.
Lei Lv, Yuliu Zhang, Yujia Zhao, Qinqin Wei, Ye Zhao, Qiyi Yi. Front Cell Neurosci 2021
1

Oligodendroglioma: A Review of Management and Pathways.
Maroun Bou Zerdan, Hazem I Assi. Front Mol Neurosci 2021
0

2-Hydroxyglutarate in Cancer Cells.
Petr Ježek. Antioxid Redox Signal 2020
23


Tumor antigens in glioma.
Takahide Nejo, Akane Yamamichi, Neil D Almeida, Yitzhar E Goretsky, Hideho Okada. Semin Immunol 2020
9

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets.
Sue Han, Yang Liu, Sabrina J Cai, Mingyu Qian, Jianyi Ding, Mioara Larion, Mark R Gilbert, Chunzhang Yang. Br J Cancer 2020
50

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Sung Choe, Hongfang Wang, Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, Gail J Roboz, Jessica K Altman, Alice S Mims, Justin M Watts, Daniel A Pollyea,[...]. Blood Adv 2020
44

Lower Grade Gliomas.
Gilbert Youssef, Julie J Miller. Curr Neurol Neurosci Rep 2020
5

Metabolite sensing and signaling in cancer.
Yi-Ping Wang, Jin-Tao Li, Jia Qu, Miao Yin, Qun-Ying Lei. J Biol Chem 2020
4


Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma.
Narges Zare Mehrjardi, Daniel Hänggi, Ulf Dietrich Kahlert. Cell Death Dis 2020
9

A Novel Four-Gene Signature Associated With Immune Checkpoint for Predicting Prognosis in Lower-Grade Glioma.
Youchao Xiao, Gang Cui, Xingguang Ren, Jiaqi Hao, Yu Zhang, Xin Yang, Zhuangzhuang Wang, Xiaolin Zhu, Huan Wang, Chunyan Hao,[...]. Front Oncol 2020
3

An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors.
Sara Verdura, Elisabet Cuyàs, Jesús Lozano-Sánchez, Cristian Bastidas-Velez, Laura Llorach-Parés, Salvador Fernández-Arroyo, Anna Hernández-Aguilera, Jorge Joven, Alfons Nonell-Canals, Joaquim Bosch-Barrera,[...]. Carcinogenesis 2019
8


Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins.
Bozena Kaminska, Bartosz Czapski, Rafal Guzik, Sylwia Katarzyna Król, Bartlomiej Gielniewski. Molecules 2019
31